-
EP3752147
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3752147
| EP3752147 - METHODS AND DOSING REGIMENS USING IBUDILAST AND A SECOND AGENT FOR CANCER THERAPY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 02.09.2022 Database last updated on 10.07.2024 | |
| Former | Request for examination was made Status updated on 20.11.2020 | ||
| Former | The international publication has been made Status updated on 17.08.2019 | Most recent event Tooltip | 02.09.2022 | Application deemed to be withdrawn | published on 05.10.2022 [2022/40] | Applicant(s) | For all designated states MediciNova, Inc. 4275 Executive Square Suite 300 La Jolla, CA 92037 / US | [2020/52] | Inventor(s) | 01 /
MATSUDA, Kazuko c/o MEDICINOVA, INC. 4275 Executive Square Suite 300 La Jolla, California 92037 / US | 02 /
MCDONALD, Kerrie c/o Lowy Cancer Research Centre The University of New South Wales Sydney, NSW 2052 / AU | [2020/52] | Representative(s) | Nederlandsch Octrooibureau P.O. Box 29720 2502 LS The Hague / NL | [2020/52] | Application number, filing date | 19751704.8 | 11.02.2019 | [2020/52] | WO2019US17430 | Priority number, date | US201862629579P | 12.02.2018 Original published format: US 201862629579 P | [2020/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019157423 | Date: | 15.08.2019 | Language: | EN | [2019/33] | Type: | A1 Application with search report | No.: | EP3752147 | Date: | 23.12.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.08.2019 takes the place of the publication of the European patent application. | [2020/52] | Search report(s) | International search report - published on: | KR | 15.08.2019 | (Supplementary) European search report - dispatched on: | EP | 22.09.2021 | Classification | IPC: | A61K31/437, A61K31/495, A61K31/4162, A61K9/00, A61P35/00 | [2021/42] | CPC: |
A61K31/437 (EP,US);
A61K31/4188 (EP,US);
A61K31/495 (EP);
A61K9/0053 (US);
A61P35/00 (EP,US);
A61K31/47 (US);
Y02A50/30 (EP)
(-)
| C-Set: |
A61K31/437, A61K2300/00 (EP);
A61K31/495, A61K2300/00 (EP) |
| Former IPC [2020/52] | A61K31/4162, A61K31/495, A61K9/00, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/52] | Title | German: | VERFAHREN UND DOSIERUNGSSCHEMA MIT IBUDILAST UND EINEM ZWEITEN MITTEL FÜR KREBSTHERAPIE | [2020/52] | English: | METHODS AND DOSING REGIMENS USING IBUDILAST AND A SECOND AGENT FOR CANCER THERAPY | [2020/52] | French: | MÉTHODES ET POSOLOGIES FAISANT APPEL À DE L'IBUDILAST ET À UN SECOND AGENT POUR LA CANCÉROTHÉRAPIE | [2020/52] | Entry into regional phase | 26.08.2020 | National basic fee paid | 26.08.2020 | Search fee paid | 26.08.2020 | Designation fee(s) paid | 26.08.2020 | Examination fee paid | Examination procedure | 26.08.2020 | Examination requested [2020/52] | 22.03.2021 | Amendment by applicant (claims and/or description) | 23.04.2022 | Application deemed to be withdrawn, date of legal effect [2022/40] | 17.05.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/40] | Fees paid | Renewal fee | 12.02.2021 | Renewal fee patent year 03 | 16.12.2021 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [IP]WO2018119262 (MEDICINOVA INC [US]) [IP] 1-15* abstract *; | [I] - Mcdonald K L ET AL, "Treating glioblastoma with a cytokine inhibitor, ibudilast in combination with temozolomide extends survival in a patient xenograft model", (20170101), URL: https://medicinova.com/wp-content/uploads/2017/07/MN-166_Glioblastoma_ASCO-poster-2017.pdf, (20210913), XP055840361 [I] 1-15 * the whole document * | [XP] - Nct03782415, "Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM", ClinicalTrials.gov archive, (20181219), URL: https://clinicaltrials.gov/ct2/history/NCT03782415?V_1=View#StudyPageTop, (20210913), XP055840410 [XP] 1-15 * the whole document * | International search | [A]WO2009009529 (MEDICINOVA INC [US], et al) [A] 1-27* See the whole document. *; | [A]US2016361298 (NOVICK PAUL [US], et al) [A] 1-27 * See the whole document. *; | [X] - "MediciNova announces positive results from a glioblastoma animal model study presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois", Globe Newswire, (20170605), pages 1 - 3, URL: https://www.globenewswire.com/news-release/2017/06/05/1008294/0/en/MediciNova-Announces-Positive-Results-from-a-Glioblastoma-Animal-Model-Study-Presented-at-the-2017-American-Society-of-Clinical-Oncology-Annual-Meeting-in-Chicago-Illinois.html, XP055631331 [X] 1-27 * See page 1. * | [X] - Kerrie L. Mcdonald et al., "Abstract 2844: MIF/ CD 74 guided therapeutic strategy for relapsed glioblastoma patients", Proceedings: AACR Annual Meeting, San Diego, (20140405), pages 1 - 4, URL: http://cancerres.aacrjournals.org/content/74/19_Supplement/2844.short, XP055497236 [X] 1-27 * See abstract. * | [X] - MCDONALD, K. L. et al., "P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide", Neuro-Oncology, (20170500), vol. 19, no. 3, page iii27, XP055631336 [X] 1-27 * See abstract. * DOI: http://dx.doi.org/10.1093/neuonc/nox036.096 |